Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000069.xml
Download PDF
Semin Liver Dis 2005; 25(1): 7-17
DOI: 10.1055/s-2005-864778
DOI: 10.1055/s-2005-864778
Acute Hepatitis C: A Multifaceted Disease
Further Information
Publication History
Publication Date:
25 February 2005 (online)
Abstract
Although acute hepatitis C virus (HCV) infection is a rare disease and typically not associated with severe clinical symptoms, it has become a disease of significant interest for clinical investigators, virologists, and immunologists alike. In the same way that acute hepatitis C provided a window of opportunity for understanding the clinical and virological aspects of HCV infection as the field was being established, it is now clear that it can provide a window into further understanding the early interaction of the virus with the host immune response. The acute phase of infection is usually considered to be the first 6 months; however, rather than defining acute HCV by the time that has passed after initial infection, it can also be defined as the biological state in which spontaneous clearance is still possible.
KEYWORDS
Acute - liver - hepatitis C virus - treatment - interferon - T cell - immune response
REFERENCES
- 1 Alter M J, Hadler S C, Judson F N et al.. Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus antibody. JAMA. 1990; 264 2231-2235
- 2 Alter H J, Purcell R H, Shih J W et al.. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med. 1989; 321 1494-1500
- 3 Schlauder G G, Leverenz G J, Amann C W et al.. Detection of the hepatitis C virus genome in acute and chronic experimental infection in chimpanzees. J Clin Microbiol. 1991; 29 2175-2179
- 4 Alberti A, Boccato S, Vario A, Benvegnu L. Therapy of acute hepatitis C. Hepatology. 2002; 36 S195-S200
- 5 Alberti A, Chemello L, Benvegnu L. Natural history of hepatitis C. J Hepatol. 1999; 31(Suppl 1) 17-24
- 6 Villano S A, Vlahov D, Nelson K E et al.. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology. 1999; 29 908-914
- 7 Thomas D L, Astemborski J, Rai R M et al.. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA. 2000; 284 450-456
- 8 Gerlach J T, Diepolder H M, Zachoval R et al.. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology. 2003; 125 80-88
- 9 Hofer H, Watkins-Riedel T, Janata O et al.. Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load. Hepatology. 2003; 37 60-64
- 10 Larghi A, Zuin M, Crosignani A et al.. Outcome of an outbreak of acute hepatitis C among healthy volunteers participating in pharmacokinetics studies. Hepatology. 2002; 36 993-1000
- 11 Bigger C B, Brasky K M, Lanford R E. DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection. J Virol. 2001; 75 7059-7066
- 12 Rahman F, Heller T, Sobao Y et al.. Effects of antiviral therapy on the cellular immune response in acute hepatitis C. Hepatology. 2004; 40 87-97
- 13 Lefrere J J, Roudot-Thoraval F, Lunel F et al.. Expertise of French laboratories in detection, genotyping, and quantification of hepatitis C virus RNA in serum. J Clin Microbiol. 2004; 42 2027-2030
- 14 Pawlotsky J M. Diagnostic testing in hepatitis C virus infection: viral kinetics and genomics. Semin Liver Dis. 2003; 23(suppl 1) 3-11
- 15 Krogsgaard K, Wantzin P, Mathiesen L R et al.. Early appearance of antibodies to hepatitis C virus in community acquired acute non-A, non-B hepatitis is associated with progression to chronic liver disease. The Copenhagen Hepatitis Acuta Programme. Scand J Infect Dis. 1990; 22 399-402
- 16 Kryczka W, Walewska-Zielecka B, Dutkiewicz E. Acute seronegative hepatitis C manifesting itself as adult giant cell hepatitis-a case report and review of literature. Med Sci Monit. 2003; 9(Suppl 3) 29-31
- 17 Morand P, Dutertre N, Minazzi H et al.. Lack of seroconversion in a health care worker after polymerase chain reaction-documented acute hepatitis C resulting from a needlestick injury. Clin Infect Dis. 2001; 33 727-729
- 18 Seeff L B, Hollinger F B, Alter H J et al.. Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative study. Hepatology. 2001; 33 455-463
- 19 Takaki A, Wiese M, Maertens G et al.. Cellular immune responses persist, humoral responses decrease two decades after recovery from a single source outbreak of hepatitis C. Nat Med. 2000; 6 578-582
- 20 Cerny A, McHutchison J G, Pasquinelli C et al.. Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif. J Clin Invest. 1995; 95 521-530
- 21 Rehermann B, Chang K M, McHutchison J G et al.. Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response, disease activity and viral load in patients with chronic hepatitis C virus infection. J Clin Invest. 1996; 98 1432-1440
- 22 Rehermann B, Chang K M, McHutchison J et al.. Differential cytotoxic T lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients. J Virol. 1996; 70 7092-7102
- 23 Chang K M, Gruener N H, Southwood S et al.. Identification of HLA-A3 and -B7-restricted CTL response to hepatitis C virus in patients with acute and chronic hepatitis C. J Immunol. 1999; 162 1156-1164
- 24 Lauer G M, Ouchi K, Chung R T et al.. Comprehensive analysis of CD8( + )-T-cell responses against hepatitis C virus reveals multiple unpredicted specificities. J Virol. 2002; 76 6104-6113
- 25 Lauer G M, Barnes E, Lucas M et al.. High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection. Gastroenterology. 2004; 127 924-936
- 26 Lechner F, Wong D K, Dunbar P R et al.. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med. 2000; 191 1499-1512
- 27 Wedemeyer H, He X -S, Nascimbeni M et al.. Impaired effector function of hepatitis C virus-specific CD8 + T cells in chronic hepatitis C virus infection. J Immunol. 2002; 169 3447-3458
- 28 Su A I, Pezacki J P, Wodicka L et al.. Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci USA. 2002; 99 15669-15674
- 29 Khakoo S I, Thio C L, Martin M P et al.. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science. 2004; 305 872-874
- 30 Diepolder H M, Zachoval R, Hoffmann R M et al.. Possible mechanism involving T lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet. 1995; 346 1006-1007
- 31 Diepolder H M, Gerlach J -T, Zachoval R et al.. Immunodominant CD4 + T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection. J Virol. 1997; 71 6011-6019
- 32 Missale G, Bertoni R, Lamonaca V et al.. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest. 1996; 98 706-714
- 33 Lamonaca V, Missale G, Urbani S et al.. Conserved hepatitis C virus sequences are highly immunogenic for CD4( + ) T cells: implications for vaccine development. Hepatology. 1999; 30 1088-1098
- 34 Gerlach J T, Diepolder H M, Jung M C et al.. Recurrence of hepatitis C virus after loss of virus-specific CD4( + ) T-cell response in acute hepatitis C. Gastroenterology. 1999; 117 933-941
- 35 Thimme R, Oldach D, Chang K M et al.. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med. 2001; 194 1395-1406
- 36 Cooper S, Erickson A L, Adams E J et al.. Analysis of a successful immune response against hepatitis C virus. Immunity. 1999; 10 439-449
- 37 Shoukry N, Grakoui A, Houghton M et al.. Memory CD8 + T cells are required for protection from persistent hepatitis C virus infection. J Exp Med. 2003; 197 1645-1655
- 38 Gerlach T J, Diepolder H M, Gruener N H et al.. Symptomatic acute hepatitis C: when to treat?. Hepatology. 1999; 30 195A
- 39 Farci P, Alter H J, Wong D C et al.. Prevention of hepatitis C virus infection in chimpanzees after antibody- mediated in vitro neutralization. Proc Natl Acad Sci USA. 1994; 91 7792-7796
- 40 Adams G, Kuntz S, Rabalais G et al.. Natural recovery from acute hepatitis C virus infection by agammaglobulinemic twin children. Pediatr Infect Dis J. 1997; 16 533-534
- 41 Christie J M, Healey C J, Watson J et al.. Clinical outcome of hypogammaglobulinaemic patients following outbreak of acute hepatitis C: 2 year follow up. Clin Exp Immunol. 1997; 110 4-8
- 42 Baumert T F, Wellnitz S, Aono S et al.. Antibodies against hepatitis C virus-like particles and viral clearance in acute and chronic hepatitis C. Hepatology. 2000; 32 610-617
- 43 Bartosch B, Dubuisson J, Cosset F L. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med. 2003; 197 633-642
- 44 Hsu M, Zhang J, Flint M et al.. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci USA. 2003; 100 7271-7276
- 45 Logvinoff C, Major M E, Oldach D et al.. Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc Natl Acad Sci USA. 2004; 101 10149-10154
- 46 Farci P, Shimoda A, Coiana A et al.. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science. 2000; 288 339-344
- 47 Fitzgerald K A, McWhirter S M, Faia K L et al.. IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat Immunol. 2003; 4 491-496
- 48 Yoneyama M, Kikuchi M, Natsukawa T et al.. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol. 2004; 5 730-737
- 49 Balachandran S, Thomas E, Barber G N. A FADD-dependent innate immune mechanism in mammalian cells. Nature. 2004; 432 401-405
- 50 Foy E, Li K, Wang C et al.. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science. 2003; 300 1145-1148
- 51 Taylor D R, Shi S T, Romano P R et al.. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science. 1999; 285 107-110
- 52 Gale M J, Korth M J, Katze M G. Repression of the PKR protein kinase by the hepatitis C virus NS5A protein: a potential mechanism of interferon resistance. Clin Diagn Virol. 1998; 10 157-162
- 53 Crotta S, Stilla A, Wack A et al.. Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C Virus envelope protein. J Exp Med. 2002; 195 35-42
- 54 Tseng C T, Klimpel G R. Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions. J Exp Med. 2002; 195 43-49
- 55 Spada E, Mele A, Berton A et al.. Multispecific T cell response and negative HCV RNA tests during acute HCV infection are early prognostic factors of spontaneous clearance. Gut. 2004; 53 1673-1681
- 56 Pham T N, MacParland S A, Mulrooney P M et al.. Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C. J Virol. 2004; 78 5867-5874
- 57 Nascimbeni M, Mizukoshi E, Bosmann M et al.. Kinetics of CD4 + and CD8 + memory T cell responses during hepatitis C virus rechallenge of previously recovered chimpanzees. J Virol. 2003; 77 4781-4793
- 58 Timm J, Lauer G, Kavanagh D G et al.. CTL escape and reversion in acute HCV infection. J Exp Med. 2004; 200 1593-1604
- 59 Erickson A L, Kimura Y, Igarashi S et al.. The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity. 2001; 15 883-895
- 60 Seifert U, Liermann H, Racanelli V et al.. Hepatitis C virus mutation affects proteasomal epitope processing. J Clin Invest. 2004; 114 250-259
- 61 Chang K M, Rehermann B, McHutchison J G et al.. Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus. J Clin Invest. 1997; 100 2376-2385
- 62 Tsai S L, Chen Y M, Chen M H et al.. Hepatitis C virus variants circumventing cytotoxic T lymphocyte activity as a mechanism of chronicity. Gastroenterology. 1998; 115 954-965
- 63 Valitutti S, Müller S, Cella M et al.. Serial triggering of many T-cell receptors by a few peptide-MHC complexes. Nature. 1995; 375 148-151
- 64 Moore C B, John M, James I R et al.. Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science. 2002; 296 1439-1443
- 65 Allen T M, Altfeld M, Yu X G et al.. Selection, transmission, and reversion of an antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus type 1 infection. J Virol. 2004; 78 7069-7078
- 66 Frasca L, Del Porto P, Tuosto L et al.. Hypervariable region 1 variants act as TCR antagonists for hepatitis C virus-specific CD4 + T cells. J Immunol. 1999; 163 650-658
- 67 Shimizu Y K, Hijikita M, Iwamoto A et al.. Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses. J Virol. 1994; 68 1494-1500
- 68 Appay V, Dunbar P R, Callan M et al.. Memory CD8 + T cells vary in differentiation phenotype in different persistent virus infections. Nat Med. 2002; 8 379-385
- 69 Francavilla V, Accapezzato D, De Salvo M et al.. Subversion of effector CD8 + T cell differentiation in acute hepatitis C virus infection: exploring the immunological mechanisms. Eur J Immunol. 2004; 34 427-437
- 70 Koziel M J, Dudley D, Wong J T et al.. Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis. J Immunol. 1992; 149 3339-3344
- 71 Koziel J M, Dudley D, Afdhal N et al.. Hepatitis C virus (HCV)-specific cytotoxic T lymphocytes recognize epitopes in the core and envelope proteins of HCV. J Virol. 1993; 67 7522-7532
- 72 Koziel M J, Dudley D, Afdhal N et al.. HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus. Identification of multiple epitopes and characterization of patterns of cytokine release. J Clin Invest. 1995; 96 2311-2321
- 73 Koziel M J, Walker B D. Characteristics of the intrahepatic cytotoxic T lymphocyte response in chronic hepatitis C virus infection. Springer Semin Immunopathol. 1997; 19 69-83
- 74 Diepolder H M, Zachoval R, Hoffmann R M et al.. The role of hepatitis C virus specific CD4 + T lymphocytes in acute and chronic hepatitis C. J Mol Med. 1996; 74 583-588
- 75 Kittlesen D J, Chianese-Bullock K A, Yao Z Q et al.. Interaction between complement receptor gC1qR and hepatitis C virus core protein inhibits T-lymphocyte proliferation. J Clin Invest. 2000; 106 1239-1249
- 76 Eisen-Vandervelde A L, Waggoner S N, Yao Z Q et al.. Hepatitis C virus core selectively suppresses interleukin-12 synthesis in human macrophages by interfering with AP-1 activation. J Biol Chem. 2004; 279 43479-43486
- 77 Yao Z Q, Ray S, Eisen-Vandervelde A et al.. Hepatitis C virus: immunosuppression by complement regulatory pathway. Viral Immunol. 2001; 14 277-295
- 78 Camma C, Almasio P, Craxi A. Interferon as treatment for acute hepatitis C. A meta-analysis. Dig Dis Sci. 1996; 41 1248-1255
- 79 Quin J. Interferon therapy for acute hepatitis C viral infection-a review by meta-analysis. Aust N Z J Med. 1997; 27 611-618
- 80 Thevenot T, Regimbeau C, Ratziu V et al.. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C in naive patients: 1999 update. J Viral Hepat. 2001; 8 48-62
- 81 Poynard T, Regimbeau C, Myers R P et al.. Interferon for acute hepatitis C. Cochrane Database Syst Rev. 2002; (1) CD000369
- 82 Jaeckel E, Cornberg M, Wedemeyer H et al.. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med. 2001; 345 1452-1457
- 83 Vogel W, Graziadei I, Umlauft F et al.. High-dose interferon-alpha2b treatment prevents chronicity in acute hepatitis C: a pilot study. Dig Dis Sci. 1996; 41 81S-85S
- 84 Licata A, Di Bona D, Schepis F et al.. When and how to treat acute hepatitis C?. J Hepatol. 2003; 39 1056-1062
- 85 Kamal S M, Ismail A, Graham C S et al.. Pegylated interferon alpha therapy in acute hepatitis C: relation to hepatitis C virus-specific T cell response kinetics. Hepatology. 2004; 39 1721-1731
- 86 Lauer G M, Lucas M, Ouchi K et al.. T cell responses during early therapy for HCV infection. Hepatology. 2003; 38 354A
- 87 Tester I A, Smyk-Pearson S, Dean S, Rosen H R. Acute hepatitis C infection following patellar tendon transplantation: immunologic correlates of recovery. Hepatology. 2003; 38 358A
- 88 Kaplan D, Sugimoto K, Ikeda F et al.. Differential mechanism of interferon-induced and spontaneous clearance of hepatitis C virus infection. Hepatology. 2003; 38 357A
- 89 Nomura H, Sou S, Tanimoto H et al.. Short-term interferon-alfa therapy for acute hepatitis C: a randomized controlled trial. Hepatology. 2004; 39 1213-1219
- 90 Major M E, Dahari H, Mihalik K et al.. Hepatitis C virus kinetics and host responses associated with disease and outcome of infection in chimpanzees. Hepatology. 2004; 39 1709-1720
Barbara RehermannM.D.
Liver Diseases Branch, NIDDK, National Institutes of Health
DHHS, Bldg. 10, Room 9B16, 10 Center Drive
Bethesda, MD 20892
Email: Rehermann@nih.gov